{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:15:40Z","timestamp":1788884140369,"version":"build-2803163510"},"reference-count":32,"publisher":"Pharmaceutical Society of Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2020,2,1]]},"DOI":"10.1248\/bpb.b19-00694","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T22:05:14Z","timestamp":1580508314000},"page":"325-333","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacological Properties of JTE-952, an Orally Available and Selective Colony Stimulating Factor 1 Receptor Kinase Inhibitor"],"prefix":"10.1248","volume":"43","author":[{"given":"Naofumi","family":"Uesato","sequence":"first","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Kakefuda","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Hata","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Ikegashira","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsuyoshi","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. <i>Trends Cell Biol.<\/i>, <b>14<\/b>, 628\u2013638 (2004)."},{"key":"2","unstructured":"2) Chapoval AI, Kamdar SJ, Kremlev SG, Evans R. CSF-1 (M-CSF) differentially sensitizes mononuclear phagocyte subpopulations to endotoxin <i>in vivo<\/i>: a potential pathway that regulates the severity of Gram-negative infections. <i>J. Leukoc. Biol.<\/i>, <b>63<\/b>, 245\u2013252 (1998)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. <i>Curr. Opin. Immunol.<\/i>, <b>18<\/b>, 39\u201348 (2006).","DOI":"10.1016\/j.coi.2005.11.006"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hume DA, Pavli P, Donahue RE, Fidler IJ. The effect of human recombinant macrophage colony-stimulating factor (CSF-1) on the murine mononuclear phagocyte system <i>in vivo.<\/i> <i>J. Immunol.<\/i>, <b>141<\/b>, 3405\u20133409 (1988).","DOI":"10.4049\/jimmunol.141.10.3405"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, Sylvestre V, Stanley ER. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. <i>Blood<\/i>, <b>99<\/b>, 111\u2013120 (2002).","DOI":"10.1182\/blood.V99.1.111"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW Jr, Ahmed-Ansari A, Sell KW, Pollard JW, Stanley ER. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op\/op) mouse. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>87<\/b>, 4828\u20134832 (1990).","DOI":"10.1073\/pnas.87.12.4828"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kawaji H, Yokomuro K, Kikuchi K, Somoto Y, Shirai Y. Macrophage colony-stimulating factor in patients with rheumatoid arthritis. <i>Nippon Ika Daigaku Zasshi<\/i>, <b>62<\/b>, 260\u2013270 (1995).","DOI":"10.1272\/jnms1923.62.260"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Seitz M, Loetscher P, Fey MF, Tobler A. Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients. <i>Br. J. Rheumatol.<\/i>, <b>33<\/b>, 613\u2013619 (1994).","DOI":"10.1093\/rheumatology\/33.7.613"},{"key":"9","unstructured":"9) Campbell IK, Rich MJ, Bischof RJ, Hamilton JA. The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. <i>J. Leukoc. Biol.<\/i>, <b>68<\/b>, 144\u2013150 (2000)."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Paniagua RT, Chang A, Mariano MM, Stein EA, Wang Q, Lindstrom TM, Sharpe O, Roscow C, Ho PP, Lee DM, Robinson WH. c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. <i>Arthritis Res. Ther.<\/i>, <b>12<\/b>, R32 (2010).","DOI":"10.1186\/ar2940"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, Hollenbaugh D, Linnemann T, Qin M, Wong J, Chu K, Doberstein SK, Williams LT. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. <i>Science<\/i>, <b>320<\/b>, 807\u2013811 (2008).","DOI":"10.1126\/science.1154370"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Wei S, Nandi S, Chitu V, Yeung YG, Yu W, Huang M, Williams LT, Lin H, Stanley ER. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. <i>J. Leukoc. Biol.<\/i>, <b>88<\/b>, 495\u2013505 (2010).","DOI":"10.1189\/jlb.1209822"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Chemel M, Le Goff B, Brion R, Cozic C, Berreur M, Amiaud J, Bougras G, Touchais S, Blanchard F, Heymann MF, Berthelot JM, Verrecchia F, Heymann D. Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. <i>Ann. Rheum. Dis.<\/i>, <b>71<\/b>, 150\u2013154 (2012).","DOI":"10.1136\/annrheumdis-2011-200096"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Akashi N, Matsumoto I, Tanaka Y, Inoue A, Yamamoto K, Umeda N, Tanaka Y, Hayashi T, Goto D, Ito S, Sekiguchi K, Sumida T. Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis. <i>Mod. Rheumatol.<\/i>, <b>21<\/b>, 267\u2013275 (2011).","DOI":"10.3109\/s10165-010-0392-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Manthey CL, Johnson DL, Illig CR, <i>et al.<\/i> JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor\/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. <i>Mol. Cancer Ther.<\/i>, <b>8<\/b>, 3151\u20133161 (2009).","DOI":"10.1158\/1535-7163.MCT-09-0255"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Conway JG, McDonald B, Parham J, <i>et al.<\/i> Inhibition of colony-stimulating-factor-1 signaling <i>in vivo<\/i> with the orally bioavailable cFMS kinase inhibitor GW2580. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>102<\/b>, 16078\u201316083 (2005).","DOI":"10.1073\/pnas.0502000102"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Conway JG, Pink H, Bergquist ML, Han B, Depee S, Tadepalli S, Lin P, Crumrine RC, Binz J, Clark RL, Selph JL, Stimpson SA, Hutchins JT, Chamberlain SD, Brodie TA. Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>326<\/b>, 41\u201350 (2008).","DOI":"10.1124\/jpet.107.129429"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Jia Y, Quinn CM, Gagnon AI, Talanian R. Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. <i>Anal. Biochem.<\/i>, <b>356<\/b>, 273\u2013281 (2006).","DOI":"10.1016\/j.ab.2006.05.006"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Rettenmier CW, Sacca R, Furman WL, Roussel MF, Holt JT, Nienhuis AW, Stanley ER, Sherr CJ. Expression of the human c-fms proto-oncogene product (colony-stimulating factor-1 receptor) on peripheral blood mononuclear cells and choriocarcinoma cell lines. <i>J. Clin. Invest.<\/i>, <b>77<\/b>, 1740\u20131746 (1986).","DOI":"10.1172\/JCI112496"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Chevalier S, Praloran V, Smith C, MacGrogan D, Ip NY, Yancopoulos GD, Brachet P, Pouplard A, Gascan H. Expression and functionality of the trkA proto-oncogene product\/NGF receptor in undifferentiated hematopoietic cells. <i>Blood<\/i>, <b>83<\/b>, 1479\u20131485 (1994).","DOI":"10.1182\/blood.V83.6.1479.bloodjournal8361479"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Miyagawa N, Homma T, Kagechika H, Shudo K, Nagai H. Effect of synthetic retinoid, TAC-101, on experimental autoimmune disease. <i>Pharmacology<\/i>, <b>67<\/b>, 21\u201331 (2003).","DOI":"10.1159\/000066783"},{"key":"22","unstructured":"22) Graczyk PP. Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. <i>J. Med. Chem.<\/i>, <b>50<\/b>, 5773\u20135779 (2007)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Wang J, Hancock MK, Dudek JM, Bi K. Cellular assays for high-throughput screening for modulators of Trk receptor tyrosine kinases. <i>Curr. Chem. Genomics<\/i>, <b>1<\/b>, 27\u201333 (2008).","DOI":"10.2174\/1875397300801010027"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Caplazi P, Baca M, Barck K, Carano RA, DeVoss J, Lee WP, Bolon B, Diehl L. Mouse models of rheumatoid arthritis. <i>Vet. Pathol.<\/i>, <b>52<\/b>, 819\u2013826 (2015).","DOI":"10.1177\/0300985815588612"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Kawanaka N, Yamamura M, Aita T, Morita Y, Okamoto A, Kawashima M, Iwahashi M, Ueno A, Ohmoto Y, Makino H. CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. <i>Arthritis Rheum.<\/i>, <b>46<\/b>, 2578\u20132586 (2002).","DOI":"10.1002\/art.10545"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Leirisalo-Repo M, Paimela L, J\u00e4\u00e4ttel\u00e4 M, Koskimies S, Repo H. Production of TNF by monocytes of patients with early rheumatoid arthritis is increased. <i>Scand. J. Rheumatol.<\/i>, <b>24<\/b>, 366\u2013371 (1995).","DOI":"10.3109\/03009749509095182"},{"key":"27","unstructured":"27) Liot\u00e9 F, Boval-Boizard B, Weill D, Kuntz D, Wautier JL. Blood monocyte activation in rheumatoid arthritis: increased monocyte adhesiveness, integrin expression, and cytokine release. <i>Clin. Exp. Immunol.<\/i>, <b>106<\/b>, 13\u201319 (1996)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Toh ML, Bonnefoy JY, Accart N, Cochin S, Pohle S, Haegel H, De Meyer M, Zemmour C, Preville X, Guillen C, Thioudellet C, Ancian P, Lux A, Sehnert B, Nimmerjahn F, Voll RE, Schett G. Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis. <i>Arthritis Rheumatol.<\/i>, <b>66<\/b>, 2989\u20133000 (2014).","DOI":"10.1002\/art.38624"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>89<\/b>, 9784\u20139788 (1992).","DOI":"10.1073\/pnas.89.20.9784"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA\/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha\/beta, and IL-1Ra. <i>Arthritis Rheum.<\/i>, <b>39<\/b>, 797\u2013809 (1996).","DOI":"10.1002\/art.1780390513"},{"key":"31","unstructured":"31) Neurath MF, Hildner K, Becker C, Schlaak JF, Barbulescu K, Germann T, Schmitt E, Schirmacher P, Haralambous S, Pasparakis M, Meyer Zum B\u00fcschenfelde KH, Kollias G, M\u00e4rker-Hermann E. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. <i>Clin. Exp. Immunol.<\/i>, <b>115<\/b>, 42\u201355 (1999)."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. <i>Rheumatology<\/i>, <b>41<\/b>, 430\u2013439 (2002).","DOI":"10.1093\/rheumatology\/41.4.430"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/43\/2\/43_b19-00694\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:07:45Z","timestamp":1695686865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/43\/2\/43_b19-00694\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b19-00694","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}